Bottom line: The evidence supports daraxonrasib’s FDA approval for a defined metastatic pancreatic cancer population, but it does not establish that Revolution Medicines is “priced for” that label—or justify a stock valuation or Hold rating. RASolute 302 demonstrated a survival benefit in previously treated metastatic disease. The final FDA indication also includes patients who are not candidates for multiagent systemic therapy, a group not described in the public trial summaries as a separately randomized population. Those distinctions matter, but they do not mean the approval lacks trial support.
What RASolute 302 tested—and what it found
RASolute 302 was an international, open-label, randomized Phase 3 trial comparing daraxonrasib with chemotherapy chosen by the investigator for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The FDA identifies the study as the efficacy trial supporting approval and describes its participants as patients whose disease had progressed after one prior line of systemic therapy.
In the trial’s overall population, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. The FDA summary reports a hazard ratio of 0.40 (95% confidence interval 0.30–0.53; p<0.0001). The peer-reviewed report in the New England Journal of Medicine (NEJM) likewise reports a hazard ratio of 0.40, with P<0.001.
The RAS G12 subgroup is a distinct analysis, not a substitute for the overall result: NEJM reports median overall survival of 13.2 months with daraxonrasib and 6.6 months with chemotherapy in that subgroup, with a hazard ratio of 0.40. Keep the subgroup and overall-population figures separate.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
How the FDA indication relates to the trial population
On August 26, 2026, the FDA approved daraxonrasib, marketed in the United States as RASONQUE, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
The randomized evidence came from previously treated metastatic disease. The final indication’s alternative wording for patients who are not candidates for multiagent systemic therapy is not described in the public trial summaries reviewed here as a separately randomized population. That is a boundary on what can be said about the trial population—not evidence that the entire approved indication lacks support, or that the FDA approved a drug without pivotal-trial evidence.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
What the approval does not establish about first-line or other cancers
RASolute 302’s result applies to the population and treatment setting studied; it does not establish daraxonrasib’s efficacy in first-line pancreatic cancer, after surgery, or in lung cancer. Revolution Medicines’ June 2026 filing describes these separate Phase 3 programs:
| Program | Population and comparison described in the filing | What it represents |
|---|---|---|
| RASolute 303 | First-line metastatic pancreatic ductal adenocarcinoma (PDAC); daraxonrasib with and without chemotherapy versus chemotherapy | A separate first-line treatment question |
| RASolute 304 | Adjuvant daraxonrasib after surgery and chemotherapy | A postoperative treatment question, distinct from metastatic disease |
| RASolute 305 | First-line metastatic PDAC; zoldonrasib with chemotherapy | A different investigational medicine in a separate first-line study |
| RASolute 309 | First-line RAS G12D PDAC; daraxonrasib plus zoldonrasib | A combination study focused on a defined mutation subtype |
| RASolve 301 | Previously treated RAS-mutant non-small-cell lung cancer (NSCLC); daraxonrasib versus docetaxel | A separate cancer type and treatment setting |
These are development programs, not extensions of the RASolute 302 survival result. Trial progress, enrollment expectations and readout timing can change; the company’s June filing presents expectations as guidance, not guaranteed dates or outcomes.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Pipeline breadth is not the same as an approved product
The June 2026 filing lists daraxonrasib, zoldonrasib (RMC-9805), elironrasib (RMC-6291) and RMC-5127 as clinical-stage RAS(ON) inhibitors, alongside additional preclinical opportunities. Their targets, development stages and evidence are not interchangeable. Apart from daraxonrasib’s approved indication, these candidates remain investigational; their presence in the pipeline does not establish approval or clinical benefit.
Cash and spending provide context, not a stock valuation
Revolution Medicines reported $3.9 billion in cash, cash equivalents and marketable securities as of June 30, 2026. That balance includes proceeds from April 2026 public offerings and convertible notes, as well as a May 2026 royalty-funding tranche. For the second quarter of 2026, the company reported research and development expense of $394.9 million and a net loss of $644.4 million. The net loss included a non-cash $151.0 million warrant fair-value charge.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
The company updated its full-year 2026 GAAP operating expense guidance to $2.1–$2.2 billion. Cash resources and planned spending help frame the company’s ability to fund development; neither, by itself, says what the shares are worth.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Can the “priced for” claim support a Hold call?
Not on the evidence available here. Establishing that the stock is priced for the approved label—or for future indications—requires a current share price or market capitalization and an explicit valuation method. The reviewed materials establish neither. They also do not establish an investor-consensus forecast. Without those inputs, “priced for” is not a verified conclusion, and a Hold rating cannot be derived from the drug’s trial result or the company’s cash balance alone.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
A grounded assessment would separate what is demonstrated from what remains uncertain:
- Established: FDA approval for the stated metastatic pancreatic adenocarcinoma indication and randomized Phase 3 survival results in previously treated metastatic disease.
- Not established by RASolute 302: efficacy in the separate first-line, adjuvant and NSCLC programs, which require their own results.
- Still needed for a valuation judgment: current market data and a transparent model that makes its assumptions about the approved indication, future trials, development spending and funding explicit.
For investors, the practical conclusion is to treat the approval and trial result as meaningful clinical evidence, while treating pipeline expansion and “priced for” language as separate questions. The available figures do not support a fresh stock-price target or an independently verified Hold verdict.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
